William D. Humphries net worth and biography

William Humphries Biography and Net Worth

Insider of Bausch Health Cos

Mr. Humphries has a strong background in Dermatology, specifically in the Pharmaceutical arena and is currently the Chief Executive Officer of Isosceles Pharmaceuticals, a biotechnology company. From August 2018 until December 2020, Mr. Humphries served as President and Group Company Chairman, Ortho Dermatologics of Bausch Health Companies Inc., where he previously served as Executive Vice President, Company Group Chairman, Dermatology from January 2017 to August 2018. From 2012 to December 2016, he served as President and Chief Executive Officer of the North American business of Merz, Inc., an affiliate of Merz Pharma Group, a specialty healthcare company. From 2004 to 2012, he served in several leadership positions with Stiefel Laboratories, Inc., a dermatology pharmaceutical company, including as its Chief Commercial Officer and then as its President beginning in 2008. Stiefel was acquired by GlaxoSmithKline in 2009. After the acquisition, Mr. Humphries served as the President of Dermatology for Stiefel, a GSK Company from 2009 until 2012. Before Stiefel, Mr. Humphries served in executive roles in sales and marketing, business development, and international marketing for Allergan, Inc., concluding as vice president of its U.S. skincare business.

What is William D. Humphries' net worth?: The estimated net worth of William D. Humphries is at least $2.59 million as of December 4th, 2020. Mr. Humphries owns 349,090 shares of Bausch Health Cos stock worth more than $2,585,011 as of December 5th. This net worth evaluation does not reflect any other assets that Mr. Humphries may own. Learn More about William D. Humphries' net worth.
How do I contact William D. Humphries?: The corporate mailing address for Mr. Humphries and other Bausch Health Cos executives is 2150 ST. ELZEAR BLVD. WEST, LAVAL A8, H7L 4A8. Bausch Health Cos can also be reached via phone at (514) 744-6792 and via email at [email protected]. Learn More on William D. Humphries' contact information.
Has William D. Humphries been buying or selling shares of Bausch Health Cos?: William D. Humphries has not been actively trading shares of Bausch Health Cos in the last ninety days. Most recently, William D. Humphries sold 114,055 shares of the business's stock in a transaction on Friday, December 4th. The shares were sold at an average price of $19.87, for a transaction totalling $2,266,272.85. Following the completion of the sale, the insider now directly owns 349,090 shares of the company's stock, valued at $6,936,418.30. Learn More on William D. Humphries' trading history.
Who are Bausch Health Cos' active insiders?: Bausch Health Cos' insider roster includes Christina Ackermann (EVP), Seana Carson (EVP), Richard DeSchutter (Director), Sam Eldessouky (CFO), Joseph Gordon (Insider), William Humphries (Insider), Steven Miller (Director), John Paulson (Director), Robert Spurr (Insider), and Amy Wechsler (Director). Learn More on Bausch Health Cos' active insiders.
Are insiders buying or selling shares of Bausch Health Cos?: In the last year, Bausch Health Cos insiders bought shares 8 times. They purchased a total of 44,316,834 shares worth more than $369,628,560.14. The most recent insider tranaction occured on August, 14th when Director John Paulson bought 34,721,118 shares worth more than $312,490,062.00. Insiders at Bausch Health Cos own 20.0% of the company. Learn More about insider trades at Bausch Health Cos.
Information on this page was last updated on 8/14/2025.

William D. Humphries Insider Trading History at Bausch Health Cos

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/4/2020	Sell	114,055	$19.87	$2,266,272.85	349,090
11/27/2020	Sell	13,663	$19.63	$268,204.69	236,518
11/24/2020	Sell	21,658	$19.63	$425,146.54	236,518
9/8/2020	Sell	5,667	$16.17	$91,635.39	235,035
8/16/2019	Buy	30,703	$21.18	$650,289.54

William D. Humphries Buying and Selling Activity at Bausch Health Cos

Bausch Health Cos Company Overview

Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.

Today's Range

Now: $7.41

$7.07

$7.55

50 Day Range

MA: $6.43

$5.90

$7.41

2 Week Range

Now: $7.41

$4.25

$8.69

Volume

4,729,236 shs

Average Volume

2,805,087 shs

Market Capitalization

$2.75 billion

P/E Ratio

7.63

Dividend Yield

N/A

Beta

0.41